President Donald Trump signed an executive order Saturday directing the federal government to accelerate reviews of several psychedelic drugs, including the Schedule I substance ibogaine [1][3].
The move matters because regulators have labeled some psychedelics as potential breakthroughs for mental‑health conditions, and a growing coalition of combat veterans and conservative legislators has been urging faster access despite lingering safety questions [2].
The order instructs the Food and Drug Administration, the Drug Enforcement Administration and the National Institute on Drug Abuse to prioritize evaluations of compounds such as psilocybin, MDMA, and ibogaine, with the goal of shortening the typical multi‑year review timeline. Officials are expected to issue new guidance within the next 180 days, a period Trump’s team said “a decisive step toward healing our nation’s wounded warriors” [3].
Supporters argue that psychedelics could address treatment‑resistant depression, PTSD, and opioid‑use disorder, conditions that have surged among veterans returning from recent conflicts. A 2024 study cited by the administration found that 30 percent of surveyed veterans with PTSD reported significant symptom reduction after supervised psilocybin therapy, prompting calls for broader availability [2].
Critics, however, warn that ibogaine’s classification as a Schedule I drug reflects concerns about its cardiotoxicity and potential for severe adverse reactions. The Substance Abuse and Mental Health Services Administration has flagged a rise in unregulated ibogaine clinics abroad, where patients sometimes experience fatal cardiac events. The executive order does not change ibogaine’s legal status but seeks to expedite the scientific review that could lead to a re‑scheduling decision [1].
Congressional oversight committees have already scheduled hearings on the federal psychedelic agenda, and several Republican representatives have pledged to introduce legislation that would streamline compassionate‑use pathways for veterans. Democrats on the Senate Health Committee have urged caution, calling for robust safety data before any policy shift.
The administration’s push aligns with a broader global trend, as countries like Canada and the United Kingdom move toward regulated therapeutic use of psychedelics. If the U.S. follows suit, it could reshape the pharmaceutical landscape and open new treatment options for millions of Americans struggling with mental‑health disorders.
**What this means**
Accelerating the review of psychedelics signals a potential shift in U.S. drug policy, moving some substances from the margins toward mainstream medical use. While the order could hasten access for veterans and others seeking alternative therapies, it also raises questions about safety oversight and the criteria that will guide any future re‑classification of Schedule I drugs.
“The order aims to accelerate federal reviews of psychedelic medicines.”
Accelerating the review of psychedelics signals a potential shift in U.S. drug policy, moving some substances from the margins toward mainstream medical use. While the order could hasten access for veterans and others seeking alternative therapies, it also raises questions about safety oversight and the criteria that will guide any future re‑classification of Schedule I drugs.
